However, most reported results were obtained from cellular and molecular experiments, and there have been few studies with intact data systematically assessing adiponectin as the molecular mechanism underlying the association between metabolic syndrome and breast cancer morbidity. This evidence concerns the gene ADIPOQ and breast carcinoma.